Terazosin

Drug Usage Statistics, United States, 2006 - 2016

Number of Prescriptions Over Time (2006 - 2016)

Rank of Top Drugs Over Time

"Rank" refers to the frequency that a given medication is prescribed within a calendar year compared to all other medications. A rank of "4" would indicate that the medication was the fourth most commonly prescribed medication.

Year Rank Change
2006 128  8
2007 119  9
2008 120  1
2009 138  18
2010 116  22
2011 129  13
Year Rank Change
2012 151  22
2013 122  29
2014 149  27
2015 166  17
2016 169  3

Patient Out-Of-Pocket Cost Over Time (2006 - 2016)

"Out-of-pocket" cost refers to the payment made by the patient (either cash price or the copay amount). This value does not include reimbursement from a third party payer (eg, Medicare or private insurance) and does not represent the total drug cost.

Usage Statistics of Related Drugs

Drug Name Total Prescriptions (2016)
Carvedilol 23,338,867
Tamsulosin Hydrochloride 22,533,462
Doxazosin Mesylate 4,010,325
Terazosin (this drug) 3,728,582
Prazosin Hydrochloride 2,432,202
Alfuzosin Hydrochloride 1,203,828

Drug Synonyms

Drug synonyms are used during the sanitation and standardization process of "cleaning" the original data source (MEPS). Occassionally, brand names may be listed below that are no longer on the market or are very infrequently used.

Brand Name Synonyms
  • Hytrin
Generic Drug Synonyms and Salts
  • Terazosin Hydrochloride
  • Terazosin Hydrochloride Anhydrous
  • Terazosin

FDA Approval Information

Established Pharmacologic Class (EPC): alpha-Adrenergic Blocker
Initial FDA approval date: 8/7/1987
First FDA applicant: Discn
First dosage form: Tablet (oral)

Prescription data source: Medical Expenditure Panel Survey (MEPS) 2006-2016. Agency for Healthcare Research and Quality (AHRQ), Rockville, MD. ClinCalc DrugStats Database version 19.0. Read more about the ClinCalc DrugStats database.

Search

Related Links

Follow Us!

New and Popular

Loading...

Open Menu

Cite This Page

Show AMA citation

©2018 - ClinCalc LLC. All rights reserved.
Disclaimer - Privacy Policy - Contact Us
Updated Jul 19, 2018
Back to Top
Top